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Abstract Earlier reports indicated that patients with the apo-
lipoprotein APOE ε4 allele responded to fish oil supplemen-
tation with a rise in serum low-density lipoprotein cholesterol
(LDL-C) compared to ε3 homozygotes. In this study, we used
clinical laboratory data to test the hypothesis that the cross-
sectional relation between RBC omega-3 fatty acid status (the
Omega-3 Index) and LDL-C was modified by APOE geno-
type. Data from 136,701 patients were available to compare
lipid biomarker levels across Omega-3 Index categories asso-
ciated with heart disease risk in all APOE genotypes. We
found no adverse interactions between APOE genotype and
the Omega-3 Index for LDL-C, LDL particle number, apoB,
HDL-C, or triglycerides. However, we did find evidence that
ε2 homozygotes lack an association between omega-3 status
and LDL-C, apoB, and LDL particle number. In summary, we
found no evidence for a deleterious relationship between lipid
biomarkers and the Omega-3 Index by APOE genotype.
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Introduction
Apolipoprotein E (APOE) is found in the triglyceride-rich
lipoproteins, i.e., very low-density lipoprotein (VLDL) parti-
cles, chylomicrons, VLDL and chylomicron remnant lipopro-
teins, intermediate density lipoproteins, and some very large
high-density lipoproteins (HDL). APOE is a ligand, along
with apoB, for the LDL (or apoB/E) receptor as well as the
LDL receptor-related protein and the VLDL receptor, and
mediates aspects of lipoprotein clearance, lipidation, and
delipidation [1]. The APOE gene is polymorphic, that is, it
can exist in three different forms, with alleles ε2, ε3, and ε4
coding for apoprotein isoforms APOE2, APOE3, and
APOE4. Any given patient will carry up to two different
isoforms, and ethnic variations in genotype frequency have
been reported [2]. Differences in APOE isoforms affect their
affinity for the LDL and VLDL receptors and the apoC
content of VLDL, thus affecting lipolytic conversion of
VLDL to LDL particles. The lipid phenotypic expression of
different genotypes varies depending on environmental
stressors (e.g., smoking, diet), comorbidities (e.g., obesity,
diabetes), and other genetic factors [3, 4]. Patients who are
ε3/ε4 or ε4/ε4 have elevated LDL levels and are at increased
risk for coronary heart disease (CHD) compared to those
with other phenotypes [5]. Accordingly, APOE genotyping
can provide information regarding the causes of some
dyslipidemias and, ultimately, risk for CHD. Knowledge of
APOE genotype can also help guide therapy as certain drugs
[3] and dietary patterns [6] affect lipid levels differently ac-
cording to genotype.
An intervention for which APOE genotype may influence
the lipid response is the use of fish oil (omega-3 fatty acids;
eicosapentaenoic acid (EPA) and docosahexaenoic acid
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(DHA)) [7–11]. One report concluded, “In APOE4 carriers,
the hypotriglyceridemic benefits [of fish oil] may be
counteracted by a potential proatherogenic shift in the choles-
terol profile” [7], and another stated, “High dose DHA sup-
plementation is associatedwith increases in total cholesterol in
E4 carriers, which appears to be due to an increase in LDL-C
and may in part negate the cardioprotective action of DHA in
this population subgroup taking omega-3” [8]. Although a
statistically significant interaction between APOE genotype
and fish oil on the low-density lipoprotein cholesterol (LDL-
C) response has been reported [8], a potentially important
question remains: are APOE4 carriers more likely to experi-
ence a rise in LDL-C with fish oil treatment than noncarriers?
This question was also recently addressed in an intervention
study by Thifalt et al. [12] and cross-sectionally in the Multi-
Ethnic Study of Atherosclerosis (MESA) [12]. In neither case
did genotype influence the relationship between omega-3 fatty
acids and LDL-C.
The purpose of this study was to explore this question
using a large clinical database in which we tested the hypoth-
esis that the APOE genotype modulates the relationship be-
tween blood omega-3 fatty acid levels and serum LDL-C. In
addition to LDL-C, we also examined the relations between
omega-3 fatty acid status and a variety of other lipid markers
[high-density lipoprotein (HDL)-C, triglycerides, LDL parti-
cle number (P), apolipoprotein B-100 (apoB)]. The biomarker
of omega-3 fatty acid status used was the Omega-3 Index, i.e.,
the red blood cell (RBC) level of EPA+DHA [13–15].
Methods
Patients All samples processed between July 2011 and April
2012 at Health Diagnostic Laboratory, Inc. (Richmond, VA)
with the following data available—age, gender, APOE geno-
type, Omega-3 Index, and lipids/lipoproteins—were included
in the cross-sectional analysis. The use of de-identified patient
data for this analysis was approved by the Copernicus Group
IRB (Durham, NC).
Laboratory Methods RBC fatty acid composition was ana-
lyzed according to the HS-Omega-3 Index® methodology as
modified from Harris et al. [15]. Fatty acid methyl esters were
generated from erythrocytes by transesterification with boron
trifluoride and analyzed by gas chromatography. Fatty acids
were identified by comparison with a standard mixture of fatty
acids characteristic of RBCs. Omega-3 Index is given as EPA
plus DHA expressed as a percentage of total identified fatty
acids after response factor correction (based on calibration
curves). APOE genotyping was performed by TaqMan assay
(Applied Biosystems Inc., Carlsbad, CA) with a success rate
of >95 %. The ε2, ε3, and ε4 single nucleotide polymor-
phisms detected were on chromosome 19 at positions
rs429358 and rs7412 with the following thymidine (T) and
cytosine (C) residues in the first position of the codon: TT, TC,
and CC, respectively. Triglyceride assay was performed using
standard automated enzymatic methods on a Roche/
Hitachi P-Modular system with Roche reagents (Roche
Diagnostics, Indianapolis, IN). ApoB was analyzed using an
immunoturbidimetric assay from Roche Diagnostics on a
Roche/Hitachi P-Modular system. LDL-C and HDL-C were
measured using direct enzymatic assays from Randox
(County Antrim, UK) on a Roche/Hitachi P-Modular system.
Low-density lipoprotein particle (LDL-P) was measured at
LipoScience (Raleigh, NC) by nuclear magnetic resonance
technology as described previously [16].
Statistical Methods Differences in lipids among the APOE
genotypes were tested using one-way ANOVA, and multiple
testing compared to the ε3/ε3 group was controlled using
Dunnett adjusted p values <0.05 for statistical significance.
The lipids were transformed using natural logarithm to im-
prove normality and homoscedasticity of the residuals; hence,
geometric means (95 % CI) were reported.
Next, the lipid/lipoprotein biomarkers (i.e., LDL-C, LDL-
P, apoB, HDL-C, triglycerides) were the dependent variables
in linear models adjusted for age and gender. To test the
hypothesis that the relations between lipid endpoints and the
Omega-3 Index were modified by APOE genotype, the
Omega-3 Index, APOE genotype, and their interaction term
were also included in all models. The Omega-3 Index was
categorized as (<4, 4–8, and >8 %) corresponding to three
different cardiovascular disease (CVD) risk levels (high, in-
termediate, and low, respectively) [13] and was alternatively
included in the model as a continuous variable for a sensitivity
analysis. To determine how the APOE genotype should be
included in the model, the following genetic inheritance
models were tested: additive, dominant, recessive, and co-
dominant. The estimated genotype association parameters
were exponentiated and reported as relative percent differ-
ences in endpoints. Analyses were performed using SAS®
software (version 9.3; SAS Institute).
Results
The mean (SD) age in this cohort (N=136,701) was 57 (15)
years, and 48 % of the samples were from males. The distri-
bution of APOE genotype is shown in Fig. 1. There was a
direct association between the genotype rank order (i.e., ε2/
ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4, ε4/ε4) and plasma levels of
LDL-C (and other atherogenic lipoprotein markers such as
apoB and LDL-P; Table 1). That is, ε2/ε2 patients had the
lowest levels and ε4/ε4 the highest. There were small differ-
ences in HDL-C and the Omega-3 Index by genotype. The
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ε2/ε2 group had an elevated geometric mean triglyceride level
that was 36 mg/dL greater than the ε3 homozygote reference
group.
The genetic inheritance model revealed that the ε4 allele’s
association with LDL-C was additive and also that the ε2
allele was codominant, meaning that homozygotes had a
diverse nonadditive association with LDL-C compared to
heterozygotes (Table 1 and Supplemental Table 1). Due to
the complex relations with LDL-C and the large sample size,
all six APOE genotypes were reported throughout. The cross-
sectional relations of lipid/lipoprotein biomarkers with the
Omega-3 Index CVD risk groups are shown by genotype in
Fig. 2. A decrease in mean atherogenic marker levels with
increasing Omega-3 Index categories was observed across all
genotypes with significant ordinal slopes (p≤0.0083, i.e.,
0.05/6 genotypes). The only exceptions were for LDL-C,
LDL-P, and apoB in the ε2/ε2 patients, and for LDL-P and
apoB in the ε2/ε4 group. HDL-C means had significant pos-
itive slopes with increasing Omega-3 Index levels.
Importantly, there were no significant genotype interactions
across Omega-3 Index CVD risk groups for LDL-C, apoB,
LDL-P, and HDL-C in age- and gender-adjusted linear models
(min. interaction p=0.41, Fig. 2, Table 2). However, the
relations between the Omega-3 Index and triglycerides were
modified by APOE genotype, varying from a −8% to a −13%
decrease per category increase in the Omega-3 Index (inter-
action p=0.0002).
A more sensitive analysis examined the Omega-3 Index as
a continuous variable and detected an interaction with APOE
genotype on LDL-C, apoB, and triglycerides (Table 2). The
APOE genotype modified the association between these lipids
and a 1 % (of total RBC fatty acids) increase in the Omega-3
Index. The interaction with APOE genotype and the Omega-3
Index on LDL-C was significant, not due to a unique associ-
ation in the ε4 subjects but due to a lack of association in the
ε2/ε2 group (−0.3 %, p=0.57) and a significant attenuation in
the ε2/ε3 group compared to the ε3 homozygotes (−0.8 vs.
−1.3, p=0.0023) (Table 3). Similarly, the interaction detected
for apoB was also due to the ε2 homozygotes’ nonassociation
and the ε2 heterzygotes’ attenuated association compared to
the other genotypes. Overall, there were no adverse relation-
ships between higher omega-3 levels and lipid biomarker
levels regardless of the APOE genotype.
Discussion
The basic question that prompted this research project was,
“are APOE4 carriers more likely to experience a rise in
LDL-C with fish oil treatment than noncarriers?” To address
this question cross-sectionally, we asked if the relationships
Fig. 1 Distribution of apolipoprotein E (APOE) genotypes in the cohort
(N=136,701) compared to those reported from two meta-analyses (Song
et al. [5] and Bennet et al. [17])
Table 1 Geometric mean (95 % CI) of lipid biomarkers by APOE genotype (N=136,701)
Variable ε2/ε2 ε2/ε3 ε2/ε4 ε3/ε3 (ref) ε3/ε4 ε4/ε4




4.62 (4.51, 4.74) 4.61a (4.59, 4.64) 4.54a (4.48, 4.59) 4.65 (4.64, 4.67) 4.59a (4.57, 4.61) 4.60 (4.54, 4.65)
HDL-cholesterol
[mg/dL]
50.7 (49.7, 51.7) 52.0a (51.8, 52.2) 51.5 (51.0, 52.0) 51.5 (51.3, 51.5) 50.6a (50.4, 50.7) 50.8 (50.4, 51.3)
Triglycerides
[mg/dL]
149a (143, 156) 120a (119, 121) 119a (117, 122) 113 (113, 114) 115a (114, 116) 116a (114, 119)
LDL-cholesterol
[mg/dL]
45.2a (44.2, 46.3) 79.9a (79.4, 80.3) 85.7a (84.7, 86.7) 94.6 (94.4, 94.8) 98.9a (98.6, 99.3) 102a (101, 104)
ApoB [mg/dL] 51.7a (50.6, 52.9) 76.2a (75.8, 76.6) 80.9a (80.0, 81.8) 86.2 (86.1, 86.4) 90.2a (89.9, 90.5) 93.8a (92.9, 94.7)
LDL-particle
[nmol/L]
694a (675, 715) 1,208a (1,201, 1,216) 1,295a (1,277, 1,313) 1,435 (1,431, 1,438) 1,504a (1,498, 1,510) 1,552a (1,531, 1,572)
a Genotype differences were tested using one-way ANOVA, and multiple testing compared to the ε3/ε3 group was controlled using Dunnett adjusted p
value <0.05
528 J. of Cardiovasc. Trans. Res. (2014) 7:526–532
between a marker of omega-3 fatty acid intake (the Omega-3
Index) and several lipid biomarkers differed by APOE
genotype.
We explored this question using a large dataset of APOE-
genotyped patients being tested for cardiovascular risk
markers. An important question is how well this clinical
dataset reflects the general population. Accordingly, we com-
pared our APOE genotype distribution with those reported in
two meta-analyses, one from over 45,000 individuals in 48
separate studies worldwide [5] and the other from 22 studies
including over 70,000 subjects [17] (Fig. 1). Distributions
were very similar. Further indicators of representativeness
were the previously reported direct associations of atherogenic
lipid markers by genotype rank order (i.e., from ε2/ε2 through
ε4/ε4) [17, 18] (Table 1). Together, these observations suggest
that this clinical cohort was reasonably representative of other
populations, and therefore, the associations observed here are
likely to be generalizable.
To address the primary research hypothesis, we tested the
cross-sectional associations between three different ranges of
the Omega-3 Index (representing different CHD risk catego-
ries) and serum lipid/lipoprotein markers across genotypes
Fig. 2 Mean (95 % CI) for lipid/
lipoprotein biomarkers by APOE
genotype shown across CHD risk
categories of the Omega-3 Index
(RBC EPA+DHA) (black bars
<4 %, white bars 4 to 8 %, gray
bars >8 %). p values for ordinal
slope interactions (adjusted for
age and gender) between APOE
genotype and Omega-3 Index
levels are given in panels. Slope
(% change) between each level
of the Omega-3 Index within
genotype was significant
(p≤0.0083, 0.05/6 genotypes)
with estimates shown below
genotypes, unless noted as not
significant (N.S.). N=136,701
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(Fig. 2); as a sensitivity analysis, we replaced the Omega-3
Index CVD risk categories with the continuous measure. If
lipid biomarkers changed with increasing omega-3 status in
some genotypes but not in others, then that would stand as
evidence that genotype does modulate the relations between
omega-3 fatty acid levels and these risk markers. We found no
interactions between the Omega-3 Index risk categories and
APOE genotype on LDL-C, LDL particle number, apoB, or
HDL-C. However, the relationship between the Index and
triglycerides did depend on genotype; compared to the refer-
ence group (ε3/ε3), the decrease in triglycerides associated
with increasing Omega-3 Index CVD risk categories ranged
from −8 % for ε2/ε3 to −13 % for ε2/ε4 and ε4/ε4. When the
Omega-3 Index categories were replaced with the continuous
measure, two additional APOE interactions were detected.
These revealed a lack of association between the Omega-3
Index with LDL-C or apoB in the ε2 homozygotes, and an
attenuated association in the ε2 heterozygotes. To the point of
this paper, there were no unique relationships between athero-
genic lipids and omega-3 status associated with the ε4 geno-
type. In addition, none of the lipid biomarkers had an adverse
cross-sectional relation with increasing Omega-3 Index levels.
This confirms the favorable relations between cardiovascular
risk profile and the Omega-3 Index recently reported in
Framingham [19].
The MESA investigators also examined the question of the
relations between omega-3 fatty acid status, lipid biomarkers,
and APOE genotype [12]. There were several differences
between their study and ours that make a comparison of
results difficult. Our study included 136,701 (vs. 2,340) pa-
tients, had minimal (vs. substantial) information on covariates,
measured RBC membrane (vs. plasma phospholipid) fatty
acids, used a combined metric of EPA+DHA (vs. each alone),
and tested different relations with lipid/lipoprotein endpoints.
Importantly, both studies reported no APOE gene-fatty acid
adverse interactions for LDL-C or LDL-P. However, the rela-
tions between EPA levels and these biomarkers were direct in
the report of Liang et al. In MESA, there was a significant
interaction by genotype (ε2) between EPA and HDL-C (direct
relations between these markers in the ε2 patients but not in
the other genotypes), whereas our study showed direct rela-
tions in all APOE genotypes. Both studies found that omega-3
fatty acid levels were slightly lower in the ε4 and ε2 carriers
(compared to the ε3 homozygotes); however, the mean dif-
ferences were small (about 0.05 %) and of doubtful clinical
significance.
Although our primary focus was on the ε4 allele, the ε2/ε2
genotype may be the more unique genotype with respect to
omega-3 fatty acids. In this group (n=860), there was no
significant association between the Omega-3 Index and
LDL-C, apoB, and LDL-P. The ε2/ε2 patients had by far the
lowest baseline LDL-C, apoB, and LDL-P concentrations, so
a lack of association perhaps has little clinical relevance.
The effects of omega-3 treatment on lipid profiles in pa-
tients carrying an ε4 allele was examined in several previous
studies, most from the University of Reading, UK. In the first,
despite finding no significant effect of genotype on serum
lipid responses to fish oil, the authors stated that, “In
APOE4 carriers, the hypotriglyceridemic benefits [of fish
oil] may be counteracted by a potential proatherogenic shift
in the cholesterol profile” [7]. This conclusion was widely
construed by many clinicians to mean that APOE4 carriers
should not be given fish oil. A follow-up study reported no
effect of genotype, but the dose of omega-3 fatty acids was
rather low [9]. In the third study [8], normal volunteers (n=20
Table 3 Cross-sectional percent differences (95 % CI) in lipids associated with a 1 % higher Omega-3 Index by APOE genotype (N=136,701)
Endpoint ε2/ε2 ε2/ε3 ε2/ε4 ε3/ε3 ε3/ε4 ε4/ε4
n=860 n=15,377 n=3,098 n=82,467 n=31,673 n=3,226




































The interactions between the Omega-3 Index and APOE genotype seen in Table 2 were due to ε2/ε2 and ε2/ε3 patients having attenuated associations
between the Omega-3 Index and lipid endpoints












Models were adjusted for age and gender and included APOE genotype
as a categorical variable, the Omega-3 Index (as either ordinal or contin-
uous), and their interaction
a See Table 3 for more detailed information
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for ε3/ε3 vs. n=18 for ε3/ε4) were given either 3.7 g/day of
DHA or 3.3 g/day of EPA. The latter had no effect on LDL-C
in either group, but the former increased LDL-C by 10% from
baseline in the ε4 carriers compared with a 4% decrease in the
reference group. Of note, apoB was not differentially affected
by genotype nor was LDL-P raised by DHA [20]. A 2012
study including 88 subjects failed to confirm the adverse DHA
effect [10]. There was no APOE genotype interaction for
postprandial lipid responses while on a fish oil diet [21] nor
did the authors find a genotype interaction for the effect of fish
oil on LDL-C. Our findings, and those from the MESA
investigators [12], are consistent with the majority view that
the relationship between omega-3 fatty acid blood levels and
LDL-C is not different in ε4 carriers relative to that in the
common wild-type genotype.
Taking a wider view, it is well known that ε4 patients are at
higher risk for CHD [5, 17] and for Alzheimer’s disease [22].
Even if the efficacy of fish oil supplements as treatments for
CHD is in question [23, 24], several studies have shown that
higher omega-3 fatty acid blood levels are associated with
decreased risk for all-cause mortality [25–28] and dementia
[29]. Direct consumption of EPA and DHA (whether from fish
oil supplements or oily fish) is by far the most important
determinant of the Omega-3 Index [30–33]. Their safety pro-
file is strong [34], and thus, their risk/benefit ratio is favorable.
Finally, because ε4 carriers may require higher doses of
EPA+DHA to raise the Omega-3 Index (as suggested in some
[35, 36] but not other [10] studies), patients carrying this allele
may be the most likely to benefit from an increased omega-3
fatty acid intake.
Strengths and Limitations
Strengths of the study include a very large sample size, the use
of an objective biomarker sensitive to changes in omega-3
fatty acid intake (the Omega-3 Index), and a broad spectrum
of unselected patients with an APOE genotype distribution
similar to that in other cohorts. There were also limitations;
this was not a randomized trial of fish oil supplementation in
patients with different APOE genotypes but a retrospective,
medical records-based analysis. As such, we had no data on
comorbidities or lifestyle factors for these patients. Perhaps
more importantly, we had no information on concomitant
drugs, and it is possible that pharmacologic regimens differed
by genotype. This could confound the relations observed here
and limit the conclusions that could be drawn from them.
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